161 related articles for article (PubMed ID: 16088366)
21. Interest in HIV vaccines among Italian injection drug users. The Network Interregionale SERT.
Serpelloni G; Vlahov D; Mazzi M; Rezza G
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):206-7. PubMed ID: 7552488
[No Abstract] [Full Text] [Related]
22. Assessment of the knowledge and beliefs of Finnish medical students regarding HIV infection and participation in AIDS vaccine trials.
Onigbogi OO; Kauhanen J; Miettola EJ
Int Q Community Health Educ; 2005-2006; 24(2):123-34. PubMed ID: 17686682
[TBL] [Abstract][Full Text] [Related]
23. Willingness to participate in HIV vaccine research in a peri-urban South African community.
Smit J; Middelkoop K; Myer L; Seedat S; Bekker LG; Stein DJ
Int J STD AIDS; 2006 Mar; 17(3):176-9. PubMed ID: 16510005
[TBL] [Abstract][Full Text] [Related]
24. Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users.
Woody GE; Metzger D; Mulvaney F
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S197-9. PubMed ID: 7865300
[No Abstract] [Full Text] [Related]
25. Pilot study assessing HIV vaccine trial readiness among female sex workers, injection and non-injection drug users, and men who have sex with men in Spain.
Etcheverry MF; de Lazzari E; Fuchs JD; Meroño M; Sierra E; Del Romero J; Evans JL; Mendez-Arancibia E; Jacques C; Rojas D; Segú M; Gatell JM; Joseph J
AIDS Behav; 2010 Jun; 14(3):607-17. PubMed ID: 19037720
[TBL] [Abstract][Full Text] [Related]
26. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.
de la Fuente L; Toro C; Soriano V; Brugal MT; Vallejo F; Barrio G; Jiménez V; Silva T;
J Clin Virol; 2006 Mar; 35(3):244-9. PubMed ID: 16143565
[TBL] [Abstract][Full Text] [Related]
27. Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users.
Dhalla S; Poole G; Singer J; Patrick DM; Wood E; Kerr T
Vaccine; 2010 Feb; 28(7):1663-7. PubMed ID: 20044049
[TBL] [Abstract][Full Text] [Related]
28. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US.
Priddy FH; Cheng AC; Salazar LF; Frew PM
Int J STD AIDS; 2006 Feb; 17(2):99-102. PubMed ID: 16464270
[TBL] [Abstract][Full Text] [Related]
29. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
[TBL] [Abstract][Full Text] [Related]
30. Sexual risk behavior among injection drug users before widespread availability of highly active antiretroviral therapy.
Rusch ML; Farzadegan H; Tarwater PM; Safaeian M; Vlahov D; Strathdee SA
AIDS Behav; 2005 Sep; 9(3):289-99. PubMed ID: 16133905
[TBL] [Abstract][Full Text] [Related]
31. Coinfection with HIV and hepatitis C virus among injection drug users in southern China.
Garten RJ; Zhang J; Lai S; Liu W; Chen J; Yu XF
Clin Infect Dis; 2005 Jul; 41 Suppl 1():S18-24. PubMed ID: 16265609
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials.
Fureman I; Meyers K; McLellan AT; Metzger D; Woody G
AIDS Educ Prev; 1997 Aug; 9(4):330-41. PubMed ID: 9376207
[TBL] [Abstract][Full Text] [Related]
33. Willingness of female sex workers in Kampala, Uganda to participate in future HIV vaccine trials: a case control study.
Mayanja Y; Abaasa A; Namale G; Price MA; Kamali A
BMC Public Health; 2020 Nov; 20(1):1789. PubMed ID: 33239018
[TBL] [Abstract][Full Text] [Related]
34. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan.
Liu JY; Lin HH; Liu YC; Lee SS; Chen YL; Hung CC; Ko WC; Huang CK; Lai CH; Chen YS; Shih YL; Chung HC; Liang SH; Lin JN
Clin Infect Dis; 2008 Jun; 46(11):1761-8. PubMed ID: 18433337
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of unprotected sex among Finnish HIV-positive and HIV-negative injecting drug users.
Kivelä PS; Krol A; Partanen AL; Ristola MA
Scand J Public Health; 2009 Jun; 37(4):357-63. PubMed ID: 19372233
[TBL] [Abstract][Full Text] [Related]
36. Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa.
Otwombe KN; Sikkema KJ; Dietrich J; de Bruyn G; van der Watt M; Gray GE
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):211-8. PubMed ID: 21765362
[TBL] [Abstract][Full Text] [Related]
37. Coping strategies of HIV-positive and HIV-negative female injection drug users: a longitudinal study.
Brook DW; Brook JS; Richter L; Whiteman M; Win PT; Masci JR; Roberto J
AIDS Educ Prev; 1999 Oct; 11(5):373-88. PubMed ID: 10555622
[TBL] [Abstract][Full Text] [Related]
38. Associations between HIV-related injection behaviour and distance to and patterns of utilisation of syringe-supply programmes.
Bruneau J; Daniel M; Kestens Y; Zang G; Généreux M
J Epidemiol Community Health; 2008 Sep; 62(9):804-10. PubMed ID: 18701731
[TBL] [Abstract][Full Text] [Related]
39. HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China.
Zhang Y; Shan H; Trizzino J; Ruan Y; Beauchamp G; Mâsse B; Ma J; Rui B; Wang J; Liu M; Wang Y; He Y; Poundstone K; Jiang Y; Jackson JB; Shao Y
Int J Infect Dis; 2007 Jul; 11(4):318-23. PubMed ID: 17321184
[TBL] [Abstract][Full Text] [Related]
40. Broadening inclusion of vulnerable populations in HIV vaccine trials.
Lau CY; Cardinali M; Sato PA; Fix A; Flores J
Expert Rev Vaccines; 2008 Mar; 7(2):259-68. PubMed ID: 18324894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
